The present invention relates to new attenuated mycroplasma bovis bacteriastrains passaged at least 110 times.Moreover, the present invention also provides immunogenic compositionscomprising live bacteria of any of those attenuated M.bovis bacteria strain, their manufacture and use for the treatment andprophylaxis of M. bovis infections and combinations withother veterinary vaccines or medicaments.